Pfizer gets fresh cancer drug rejection from NICE
LONDON (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.
The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.
(Reporting by Ben Hirschler; Editing by David Cowell)
- Tweet this
- Share this
- Digg this
- Pro-independence Scots narrow gap to victory ahead of vote - poll
- Kremlin adviser says military strategy to reflect Ukraine crisis, NATO expansion - RIA
- Low-carb diets may beat low-fat options for weight loss, heart health
- Europe drafts emergency energy plan with eye on Russia gas shut-down
- UK's fate in the balance as poll shows record support for Scottish independence